請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4629
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李心予 | |
dc.contributor.author | Kuan-Ying Lu | en |
dc.contributor.author | 盧冠穎 | zh_TW |
dc.date.accessioned | 2021-05-14T17:44:20Z | - |
dc.date.available | 2015-07-31 | |
dc.date.available | 2021-05-14T17:44:20Z | - |
dc.date.copyright | 2015-07-31 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-29 | |
dc.identifier.citation | [1] D.G. Zaridze, P. Boyle, M. Smans, International trends in prostatic cancer, Int J Cancer 33 (1984) 223-230.
[2] M.M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, F. Bray, International variation in prostate cancer incidence and mortality rates, Eur Urol 61 (2012) 1079-1092. [3] H. Kuruma, S. Egawa, Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates, Eur Urol 63 (2013) 583-584. [4] A. Pongtippan, A. Malpica, C. Levenback, M.T. Deavers, E.G. Silva, Skene's gland adenocarcinoma resembling prostatic adenocarcinoma, Int J Gynecol Pathol 23 (2004) 71-74. [5] S.L. Tepper, J. Jagirdar, D. Heath, S.A. Geller, Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration, Arch Pathol Lab Med 108 (1984) 423-425. [6] M.K. Dodson, W.A. Cliby, G.L. Keeney, M.F. Peterson, K.C. Podratz, Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen, Gynecol Oncol 55 (1994) 304-307. [7] P. Saraon, K. Jarvi, E.P. Diamandis, Molecular alterations during progression of prostate cancer to androgen independence, Clin Chem 57 (2011) 1366-1375. [8] G. Attard, D. Sarker, A. Reid, R. Molife, C. Parker, J.S. de Bono, Improving the outcome of patients with castration-resistant prostate cancer through rational drug development, Br J Cancer 95 (2006) 767-774. [9] B. Mellado, M. Marin Aguilera, M.V. Pereira, Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets, Arch Esp Urol 66 (2013) 453-462. [10] N.M. Hoosein, D.D. Boyd, W.J. Hollas, A. Mazar, J. Henkin, L.W. Chung, Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines, Cancer Commun 3 (1991) 255-264. [11] Y.C. Lu, W.C. Weng, H. Lee, Functional Roles of Calreticulin in Cancer Biology, Biomed Res Int 2015 (2015) 526524. [12] T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A.C. Bjorklund, D.C. Chapman, M. Durchschlag, N. Joza, G. Pierron, P. van Endert, J. Yuan, L. Zitvogel, F. Madeo, D.B. Williams, G. Kroemer, Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, Embo j 28 (2009) 578-590. [13] C. Clarke, M.J. Smyth, Calreticulin exposure increases cancer immunogenicity, Nat Biotechnol 25 (2007) 192-193. [14] M.P. Chao, S. Jaiswal, R. Weissman-Tsukamoto, A.A. Alizadeh, A.J. Gentles, J. Volkmer, K. Weiskopf, S.B. Willingham, T. Raveh, C.Y. Park, R. Majeti, I.L. Weissman, Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47, Sci Transl Med 2 (2010) 63ra94. [15] A. Alaiya, U. Roblick, L. Egevad, A. Carlsson, B. Franzen, D. Volz, S. Huwendiek, S. Linder, G. Auer, Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma, Anal Cell Pathol 21 (2000) 1-9. [16] M. Alur, M.M. Nguyen, S.E. Eggener, F. Jiang, S.S. Dadras, J. Stern, S. Kimm, K. Roehl, J. Kozlowski, M. Pins, M. Michalak, R. Dhir, Z. Wang, Suppressive roles of calreticulin in prostate cancer growth and metastasis, Am J Pathol 175 (2009) 882-890. [17] F. Hao, M. Tan, X. Xu, J. Han, D.D. Miller, G. Tigyi, M.Z. Cui, Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha, Biochim Biophys Acta 1771 (2007) 883-892. [18] Y.S. Hwang, J.C. Hodge, N. Sivapurapu, P.F. Lindholm, Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity, Mol Carcinog 45 (2006) 518-529. [19] G.V. Raj, J.A. Sekula, R. Guo, J.F. Madden, Y. Daaka, Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB, Prostate 61 (2004) 105-113. [20] C.L. Chang, J.J. Liao, W.P. Huang, H. Lee, Lysophosphatidic acid inhibits serum deprivation-induced autophagy in human prostate cancer PC-3 cells, Autophagy 3 (2007) 268-270. [21] Y. Hasegawa, M. Murph, S. Yu, G. Tigyi, G.B. Mills, Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells, Mol Oncol 2 (2008) 54-69. [22] P.Y. Wu, Y.C. Lin, S.Y. Lan, Y.L. Huang, H. Lee, Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells, Biochem Biophys Res Commun 437 (2013) 440-445. [23] C.E. Lin, S.U. Chen, C.C. Lin, C.H. Chang, Y.C. Lin, Y.L. Tai, T.L. Shen, H. Lee, Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells, PLoS One 7 (2012) e41096. [24] Y. Kihara, M. Maceyka, S. Spiegel, J. Chun, Lysophospholipid receptor nomenclature review: IUPHAR Review 8, Br J Pharmacol 171 (2014) 3575-3594. [25] S. Ishii, K. Noguchi, K. Yanagida, Non-Edg family lysophosphatidic acid (LPA) receptors, Prostaglandins Other Lipid Mediat 89 (2009) 57-65. [26] C.W. Lee, R. Rivera, S. Gardell, A.E. Dubin, J. Chun, GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5, J Biol Chem 281 (2006) 23589-23597. [27] W.J. Wasilenko, J. Cooper, A.J. Palad, K.D. Somers, P.F. Blackmore, J.S. Rhim, G.L. Wright, Jr., P.F. Schellhammer, Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP, Prostate 30 (1997) 167-173. [28] M.G. Todorova, E. Fuentes, B. Soria, A. Nadal, I. Quesada, Lysophosphatidic acid induces Ca2+ mobilization and c-Myc expression in mouse embryonic stem cells via the phospholipase C pathway, Cell Signal 21 (2009) 523-528. [29] A.R. Means, Calcium, calmodulin and cell cycle regulation, FEBS Lett 347 (1994) 1-4. [30] D.M. Savarese, J.T. Russell, A. Fatatis, L.A. Liotta, Type IV collagen stimulates an increase in intracellular calcium. Potential role in tumor cell motility, J Biol Chem 267 (1992) 21928-21935. [31] E.C. Kohn, R. Alessandro, J. Spoonster, R.P. Wersto, L.A. Liotta, Angiogenesis: role of calcium-mediated signal transduction, Proc Natl Acad Sci U S A 92 (1995) 1307-1311. [32] P. Nicotera, B. Zhivotovsky, S. Orrenius, Nuclear calcium transport and the role of calcium in apoptosis, Cell Calcium 16 (1994) 279-288. [33] M. Waser, N. Mesaeli, C. Spencer, M. Michalak, Regulation of calreticulin gene expression by calcium, J Cell Biol 138 (1997) 547-557. [34] Y. Zeng, Y. Kakehi, M.A. Nouh, H. Tsunemori, M. Sugimoto, X.X. Wu, Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia, Prostate 69 (2009) 283-292. [35] V. Härmä, M. Knuuttila, J. Virtanen, T. Mirtti, P. Kohonen, P. Kovanen, A. Happonen, S. Kaewphan, I. Ahonen, O. Kallioniemi, R. Grafström, J. Lötjönen, M. Nees, Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models, Oncogene 31 (2012) 2075-2089. [36] I. Martinez-Corral, M.H. Ulvmar, L. Stanczuk, F. Tatin, K. Kizhatil, S.W. John, K. Alitalo, S. Ortega, T. Makinen, Nonvenous origin of dermal lymphatic vasculature, Circ Res 116 (2015) 1649-1654. [37] S. Patan, Vasculogenesis and angiogenesis, Cancer Treat Res 117 (2004) 3-32. [38] P. Carmeliet, Angiogenesis in health and disease, Nat Med 9 (2003) 653-660. [39] P. Kapoor, R. Deshmukh, VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study, J Oral Maxillofac Pathol 16 (2012) 330-337. [40] C. Cursiefen, L. Chen, L.P. Borges, D. Jackson, J. Cao, C. Radziejewski, P.A. D'Amore, M.R. Dana, S.J. Wiegand, J.W. Streilein, VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment, J Clin Invest 113 (2004) 1040-1050. [41] M. Tawada, S. Hayashi, Y. Ikegame, S. Nakashima, K. Yoshida, Possible involvement of tumor-producing VEGF-A in the recruitment of lymphatic endothelial progenitor cells from bone marrow, Oncol Rep 32 (2014) 2359-2364. [42] J. Woolard, W.Y. Wang, H.S. Bevan, Y. Qiu, L. Morbidelli, R.O. Pritchard-Jones, T.G. Cui, M. Sugiono, E. Waine, R. Perrin, R. Foster, J. Digby-Bell, J.D. Shields, C.E. Whittles, R.E. Mushens, D.A. Gillatt, M. Ziche, S.J. Harper, D.O. Bates, VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression, Cancer Res 64 (2004) 7822-7835. [43] W.K. Ranasinghe, L. Xiao, S. Kovac, M. Chang, C. Michiels, D. Bolton, A. Shulkes, G.S. Baldwin, O. Patel, The role of hypoxia-inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers, PLoS One 8 (2013) e54251. [44] N. Ferrara, H.P. Gerber, J. LeCouter, The biology of VEGF and its receptors, Nat Med 9 (2003) 669-676. [45] A. Fraga, R. Ribeiro, P. Principe, C. Lopes, R. Medeiros, Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings, Clin Genitourin Cancer (2015). [46] T. Hashimoto, F. Shibasaki, Hypoxia-inducible factor as an angiogenic master switch, Front Pediatr 3 (2015) 33. [47] J. Chen, S. De, J. Brainard, T.V. Byzova, Metastatic properties of prostate cancer cells are controlled by VEGF, Cell Commun Adhes 11 (2004) 1-11. [48] J.L. Duque, K.R. Loughlin, R.M. Adam, P.W. Kantoff, D. Zurakowski, M.R. Freeman, Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer, Urology 54 (1999) 523-527. [49] E.K. Amankwah, T.A. Sellers, J.Y. Park, Gene variants in the angiogenesis pathway and prostate cancer, Carcinogenesis 33 (2012) 1259-1269. [50] D. Vuppalanchi, T.T. Merianda, C. Donnelly, A. Pacheco, G. Williams, S. Yoo, R.R. Ratan, D.E. Willis, J.L. Twiss, Lysophosphatidic acid differentially regulates axonal mRNA translation through 5'UTR elements, Mol Cell Neurosci 50 (2012) 136-146. [51] K. Bandoh, J. Aoki, A. Taira, M. Tsujimoto, H. Arai, K. Inoue, Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors, FEBS Lett 478 (2000) 159-165. [52] J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, R.A. Bundey, P.C. Prodanovich, P. Fagan, C.S. Baccei, A.M. Santini, J.H. Hutchinson, T.J. Seiders, T.A. Parr, P. Prasit, J.F. Evans, D.S. Lorrain, A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model, Br J Pharmacol 160 (2010) 1699-1713. [53] T. Virag, D.B. Elrod, K. Liliom, V.M. Sardar, A.L. Parrill, K. Yokoyama, G. Durgam, W. Deng, D.D. Miller, G. Tigyi, Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors, Mol Pharmacol 63 (2003) 1032-1042. [54] G.N. Kiss, J.I. Fells, R. Gupte, S.C. Lee, J. Liu, N. Nusser, K.G. Lim, R.M. Ray, F.T. Lin, A.L. Parrill, B. Sumegi, D.D. Miller, G. Tigyi, Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions, Mol Pharmacol 82 (2012) 1162-1173. [55] Y. Hasegawa, J.R. Erickson, G.J. Goddard, S. Yu, S. Liu, K.W. Cheng, A. Eder, K. Bandoh, J. Aoki, R. Jarosz, A.D. Schrier, K.R. Lynch, G.B. Mills, X. Fang, Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor, J Biol Chem 278 (2003) 11962-11969. [56] H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, M. Yagi, M. Sato, R. Suzuki, H. Murooka, T. Sakai, T. Nishitoba, D.S. Im, H. Nochi, K. Tamoto, H. Tomura, F. Okajima, Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors, Mol Pharmacol 64 (2003) 994-1005. [57] J.M. Ossewaarde, A. de Vries, T. Bestebroer, A.F. Angulo, Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chlamydia sp. strains, Applied and Environmental Microbiology 62 (1996) 328-331. [58] V. Georget, J.M. Lobaccaro, B. Terouanne, P. Mangeat, J.C. Nicolas, C. Sultan, Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor, Mol Cell Endocrinol 129 (1997) 17-26. [59] Z.Q. Huang, J. Li, J. Wong, AR possesses an intrinsic hormone-independent transcriptional activity, Mol Endocrinol 16 (2002) 924-937. [60] L. Zhang, M. Johnson, K.H. Le, M. Sato, R. Ilagan, M. Iyer, S.S. Gambhir, L. Wu, M. Carey, Interrogating androgen receptor function in recurrent prostate cancer, Cancer Res 63 (2003) 4552-4560. [61] J.T. Isaacs, The biology of hormone refractory prostate cancer. Why does it develop?, Urol Clin North Am 26 (1999) 263-273. [62] N. Zhu, Z. Wang, Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells, Cancer Res 59 (1999) 1896-1902. [63] S. Tai, Y. Sun, J.M. Squires, H. Zhang, W.K. Oh, C.Z. Liang, J. Huang, PC3 is a cell line characteristic of prostatic small cell carcinoma, Prostate 71 (2011) 1668-1679. [64] F. Alimirah, J. Chen, Z. Basrawala, H. Xin, D. Choubey, DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation, FEBS Lett 580 (2006) 2294-2300. [65] R.J. Stewart, D. Panigrahy, E. Flynn, J. Folkman, Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts, J Urol 165 (2001) 688-693. [66] J. Li, E. Wang, F. Rinaldo, K. Datta, Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway, Oncogene 24 (2005) 5510-5520. [67] W.C. Weng, K.H. Lin, P.Y. Wu, Y.C. Lu, Y.C. Weng, B.J. Wang, Y.F. Liao, W.M. Hsu, W.T. Lee, H. Lee, Calreticulin Regulates VEGF-A in Neuroblastoma Cells, Mol Neurobiol (2014). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4629 | - |
dc.description.abstract | 鈣網蛋白 (Calreticulin, CRT) 為一種多功能之伴護蛋白 (Chaperone protein),在許多種類的癌症組織切片中,皆發現CRT蛋白質的表現量相對高於正常組織。而在我們實驗室先前的研究中,已證實CRT會促進胃癌和膀胱癌之腫瘤生長及轉移。但在攝護腺癌中,CRT所扮演的角色及其調控機制並不清楚。本研究中,我們首先針對早期攝護腺癌細胞株LNCaP與晚期攝護腺癌細胞株PC-3進行比較,發現PC-3的細胞貼附能力以及細胞增生能力皆顯著高於LNCaP,並且PC-3比LNCaP表現更多量的CRT與血管內皮生長因子A型(Vascular endothelial growth factor A, VEGF-A)。為了進一步研究CRT在攝護腺癌細胞癌化中扮演的角色,我們建立了穩定降低CRT表現之PC-3細胞株,結果顯示抑制CRT之表現會顯著地降低PC-3之細胞貼附能力以及細胞增生能力,此外VEGF-A之表現量顯著下降。由這些結果可推論CRT為影響攝護腺癌細胞癌化之重要調控因子。接著我們試著找出造成CRT於晚期攝護腺癌細胞株增量表現的上游調控分子。水解磷酸脂 (Lysophosphatidic acid, LPA) 是一種多功能的信息傳遞分子,已知會影響攝護腺癌細胞株之增殖 (proliferation)、轉移 (migration) 以及侵入 (invasion)。先前已有研究顯示,在小鼠D3 ES (D3 embryo stem cells) 細胞中,LPA會經由磷脂酶C(phospholipase C, PLC)的路徑調控內質網 (endoplasmic reticulum, ER) 的鈣離子 (Ca2+) 流失。另一方面,在小鼠纖維母細胞NIH/3T3細胞株中,ER的Ca2+流失會活化CRT的啟動子。根據這些研究,我們假設在攝護腺癌細胞株中,LPA會促進CRT的表現。實驗結果證實,在晚期攝護腺癌細胞株PC-3中,LPA會促進CRT之RNA和protein表現。但在早期攝護腺癌細胞株LNCaP中,LPA卻無促進CRT表現之作用。而利用LPA受器之拮抗劑 (antagonist) 或促進劑 (agonist) 以及基因敲落 (gene knockdown) 或基因大量表達 (gene overexpression) 的方式來對LPA受器進行操作的實驗中,我們發現在晚期攝護腺癌細胞株PC-3中,LPA可經由細胞表面受器LPA1和LPA3促進CRT的表現; 但同時LPA亦可經由細胞表面受器LPA2抑制CRT的表現。這些結果顯示,透過調整細胞表面的LPA受器表達模式 (LPA receptor expression pattern) ,或可有效調控CRT之表現並進一步控制攝護腺癌細胞之癌化。 | zh_TW |
dc.description.abstract | Calreticulin (CRT), a multifunctional Ca2+-binding chaperone, has been shown to associate with poor prognosis in gastric cancer and bladder cancer. However, the roles of CRT in prostate cancer remain elusive. Prostate cancer is one of the most frequently diagnosed cancers in males and PC-3 is a popular cell model for investigating late stage prostate cancer. By comparing early stage prostate cancer cell line LNCaP with late stage prostate cancer cell line PC-3, we found that PC-3 showed higher cell adherent ability, cell proliferation ability and higher expression of vascular endothelial growth factor-A (VEGF-A), which is an important regulator for angiogenesis and tumor growth. Furthermore, knockdown of CRT in PC-3 caused lower cell adherent ability , cell proliferation ability and VEGF-A expression. These results indicate that CRT may be a poor prognosis factor in prostate cancer. Subsequently we further investigate the upstream regulation mechanism for calreticulin expression. Lysophosphatidic acid (LPA), a low molecular weight lipid, has been proved to stimulate cell migration, invasion and proliferation in prostate cancer cells. It has been demonstrated that LPA evoked Ca2+ mobilization from the lumen of the endoplasmic reticulum (ER) via phospholipase C (PLC) pathway. On the other hand, depletion of Ca2+ from ER activated CRT promoter activity in NIH/3T3 cells. Based on these evidences, we hypothesized that LPA regulate CRT expression in prostate cancer cells. By using RT-qPCR and Western Blotting, we found that CRT expression is up-regulated both in mRNA and protein level after LPA treatment. Pharmacological blockade by LPA1-specific antagonist AM966 or LPA1/3-selective antagonist Ki16425 inhibits the enhancement effect of LPA on CRT expression. In addition, LPA-dependent CRT expression was abolished in LPA1 and LPA3 stable knockdown PC-3 cells. Furthermore, activation of LPA3 by LPA3-specific agonist OMPT enhances CRT expression. These results indicated that activation of LPA1 and LPA3 up-regulate the expression of CRT. On the contrary, activation of LPA2 by LPA2-selective agonist MDP and LPA2-specific agonist GRI977143 impaired CRT expression. In conclusion, our findings suggested that, LPA1/3 and LPA2 inversely regulate CRT expression and subsequently regulate cell adhesion, cell proliferation and VEGF-A expression in PC-3 cells. | en |
dc.description.provenance | Made available in DSpace on 2021-05-14T17:44:20Z (GMT). No. of bitstreams: 1 ntu-104-R02b21004-1.pdf: 1555487 bytes, checksum: b78da8651a14232f7b6aa85d645a295d (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Contents
致 謝 I 摘 要 II Abstract IV Content VI Introduction 1 Prostate cancer 1 Calreticulin in prostate cancer 2 Lysophosphatidic acid in prostate cancer 4 VEGF-A in prostate cancer 5 Rationale 7 Material and Methods 8 Cell culture 8 Puromycin lethal dose test of PC-3 cells 8 Transfection and selection of stable cell lines 9 Pharmacological treatment 9 Reverse transcription (RT) and Real-time PCR 11 Mycoplasma test 13 Western blot analysis 14 Adhesion assay 15 Proliferation assay 15 Statistical analysis 16 Results 17 PC-3 cells show higher levels of cell adhesion, proliferation, CRT / VEGF-A expression compared with LNCaP prostate cancer cells. 17 Knockdown of CRT decreases VEGF-A expression, cell adherent ability and cell proliferation ability in PC-3 cells. 17 LPA induces calreticulin expression in late stage prostate cancer cell line PC-3, but not early stage prostate cancer cell line LNCaP . 18 LPA receptor mRNA profile comparison between high metastatic potential PC-3 and low metastatic potential LNCaP prostate cancer cells 18 LPA1 and LPA3 are involved in up-regulation of CRT expression in PC-3 cells 19 LPA2 is involved in down-regulation of CRT mRNA expression in PC-3 cells 20 Discussion 21 Reference 24 Figures 30 Supplemental Figures 44 | |
dc.language.iso | en | |
dc.title | 水解磷酸脂促進PC-3前列腺癌細胞株之鈣網蛋白表現 | zh_TW |
dc.title | Lysophosphatidic acid upregulates calreticulin expression
in PC-3 human prostate cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李明學,張正琪,黃元勵 | |
dc.subject.keyword | 攝護腺癌,鈣網蛋白,水解磷酸脂,水解磷酸脂受器,血管內皮生長因子A, | zh_TW |
dc.subject.keyword | Prostate cancer,Calreticulin,Lysophosphatidic acid,Vascular endothelial growth factor-A, | en |
dc.relation.page | 49 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2015-07-29 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf | 1.52 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。